Anti-CD3 mAb treatment cures PDL1-/-NOD mice of diabetes but precipitates fatal myocarditis

Clinical Immunology

Volumn 140, Issue 1, 2011, Pages 47-53

  Mfarrej, Bechara ^a   Keir, Mary ^a,b   Dada, Shirine ^a   Trikudanathan, Subbulaxmi ^a   Sayegh, Mohamed H ^a   Sharpe, Arlene H ^a,b   Guleria, Indira ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti CD3 mAb treatment; Diabetes; Myocarditis; PD1 PDL1 costimulatory pathway; PDL1 deficient mice

Indexed keywords

MONOCLONAL ANTIBODY CD3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; GENERAL CONDITION DETERIORATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MYOCARDITIS; MYOSITIS; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; WASTING SYNDROME; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CELL SEPARATION; DIABETES MELLITUS, TYPE 1; FLOW CYTOMETRY; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MYOCARDITIS;

EID: 79958767886     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.03.011     Document Type: Article

References (26)

1. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
2. Rothstein D.M., Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 2003, 196:85-108.
3. Khoury S.J., Sayegh M.H. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004, 20:529-538.
4. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5:1365-1369.
5. Ozkaynak E., Wang L., Goodearl A., McDonald K., Qin S., O'Keefe T., Duong T., Smith T., Gutierrez-Ramos J.C., Rottman J.B., Coyle A.J., Hancock W.W. Programmed death-1 targeting can promote allograft survival. J. Immunol. 2002, 169:6546-6553.
6. Li X.C., Rothstein D.M., Sayegh M.H. Costimulatory pathways in transplantation: challenges and new developments. Immunol. Rev. 2009, 229:271-293.
7. Nurieva R.I., Liu X., Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol. Rev. 2009, 229:88-100.
8. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., Shin T., Tsuchiya H., Pardoll D.M., Okumura K., Azuma M., Yagita H. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 2002, 169:5538-5545.
9. Eppihimer M.J., Gunn J., Freeman G.J., Greenfield E.A., Chernova T., Erickson J., Leonard J.P. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002, 9:133-145.
10. Schoop R., Wahl P., Le Hir M., Heemann U., Wang M., Wuthrich R.P. Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol. Dial. Transplant. 2004, 19:2713-2720.
11. Nakazawa A., Dotan I., Brimnes J., Allez M., Shao L., Tsushima F., Azuma M., Mayer L. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 2004, 126:1347-1357.
12. Ansari M.J., Chitnis T., Smith R.N., Yagita H., Akiba H., Azuma M., Iwai H., Auchincloss H., Khoury S., Sayegh M.H. The programmed death-1 pathway regulates autoimmune diabetes in NOD mice. J. Exp. Med. 2003, 198:63-69.
13. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:123-127.
14. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J. Med. 2002, 346:1692-1698.
15. Herold K.C., Gitelman S., Greenbaum C., Puck J., Hagopian W., Gottlieb P., Sayre P., Bianchine P., Wong E., Seyfert-Margolis V., Bourcier K., Bluestone J.A. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5years. Clin. Immunol. 2009, 132:166-173.
16. Perruche S., Zhang P., Liu Y., Saas P., Bluestone J.A., Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med. 2008, 14:528-535.
17. You S., Leforban B., Garcia C., Bach J.F., Bluestone J.A., Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6335-6340.
18. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?. Nat. Rev. Endocrinol. 2010, 6:149-157.
19. Nishimura H., Minato N., Nakano T., Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 1998, 10:1563-1572.
20. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
21. Wang J., Yoshida T., Nakaki F., Hiai H., Okazaki T., Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11823-11828.
22. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., Koulmanda M., Freeman G.J., Sayegh M.H., Sharpe A.H. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 2006, 203:883-895.
23. Guleria I., Khosroshahi A., Ansari M.J., Habicht A., Azuma M., Yagita H., Noelle R.J., Coyle A., Mellor A.L., Khoury S.J., Sayegh M.H. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 2005, 202:231-237.
24. Herold K.C., Bluestone J.A., Montag A.G., Parihar A., Wiegner A., Gress R.E., Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992, 41:385-391.
25. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A., Wu H., Chen M.L., Gandhi R., Miller A., Maron R., Weiner H.L. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J. Neurol. Sci. 2008, 274:9-12.
26. Bour-Jordan H., Thompson H.L., Bluestone J.A. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J. Immunol. 2005, 175:5649-5655.